BELLEVUE, Wash., May 13, 2014 (GLOBE NEWSWIRE) -- VitaCig, Inc. an mCig, Inc. (OTCQB:MCIG) Company, is pleased to announce that it has initiated the implementation of best-in class testing, quality control, and chain of custody standards within the VitaCig manufacturing process.
As of May 15, 2014, VitaCig products will be manufactured under the following guidelines:
Metallic and Electronic Components – All metallic and electronic components utilized in the production of the VitaCig will be independently tested as per the compliance requirements of RoHS (Restriction of Hazardous Substance Directive) and the European CE Mark.
Vitamins, Phytonutrients, Liquid ingredients – Batches of Vitamins, Phytonutrients, and any other liquid ingredients found in the VitaCig will be independently tested by Intertek Group, PLC for the following substances:
B-myrcene or D-limonene or eucalyptol (depending on respective sample), ascorbic acid, alpha-tocopherol acetate, vitamin A palmitate, vitamin B1, CoQ10, organophosphate pesticides, microbes, cadmium, lead, nickel, arsenic, mercury, and aluminum.
Following the receipt of successful test results from Intertek, VitaCig ingredients will be cleared for insertion. Each batch of ingredients will be catalogued and labeled with both nutritional values as well as an expiration date. This label will be annexed to each individual VitaCig package utilizing the same manufacturing technology that is used in the pharmaceutical and nutritional supplement industry. Once packaged, VitaCig products will be shipped to our newly leased temperature-controlled storage center in Pennsylvania, USA where they will remain until order fulfillment.
"Long before any FDA Proposals, our team was initiation a plan for the implementation of standards for independent testing and chain of custody for all VitaCig products. We view VitaCig not as an electronic cigarette but as a medical delivery device. That is why we must ensure that every ingredient found within the VitaCig can be properly accounted for and independently tested for potential hazardous compounds. Independent testing also provides the added benefit of testing our vitamins and phytonutrients for potency and efficacy." Said Paul Rosenberg, CEO of mCig, Inc.
"When deciding on potential lab partners we were presented with several options. Most labs had lower testing standards, and were less costly than Intertek. Ultimately, we chose Intertek Group PLC, a multi-billion dollar company because we felt their reputation within the pharmaceutical testing industry would demonstrate our commitment to ingredient transparency which in turn would help promote VitaCig products as best-in class nicotine-free electronic cigarettes."
"With the implementation of these standards, we are truly setting the bar in the industry and positioning VitaCig to be distributed on a national scale not only in conventional distribution points but higher value distribution points that require nutritional values, chain of custody, and quality control as part of inventory inclusion." Said Mark Linkhorst, CEO of VitaCig, Inc.
"Since joining mCig and VitaCig, I have received many questions regarding the efficiency of direct inhalation of vitamins. In my view, the educated consumer is watching closely with genuine intellectual curiosity. Based on my knowledge of how the industry currently operates, the implementation of the standards announced today will separate the VitaCig brand from all others via transparency in ingredient labeling and objective quality assurance. This will further assist in the educational process for consumers who will start viewing VitaCig products in the same light as other independently tested nutritional supplements." Said Dr. Khary Bryan Chief Technical Officer of VitaCig, Inc.
About mCig, Inc.
mCig, Inc. (OTCQB:MCIG) is a technology company focused on two long-term secular trends sweeping the globe: (1) The decriminalization and legalization of marijuana for medicinal or recreational purposes (2) The adoption of electronic vaporizing cigarettes (commonly known as "eCigs") by the world's 1.2 Billion smokers. The company manufactures and retails the mCig – the world's most affordable vaporizer priced at only $10. Designed in the USA – the mCig provides a superior smoking experience by heating plant material, waxes, and oils delivering a smoother inhalation experience. The company also owns Vapolution, Inc. which manufactures and retails home-use vaporizers such as the Vapolution 2.0. Through its wholly owned subsidiary, VitaCig, Inc. the company manufactures and retails the VitaCig, a $2 nicotine-free eCig that delivers a water-vapor mixed with vitamins and organic flavors. Through its wholly owned subsidiary, LiqCig, Inc. the company is engaged in the development of the world's first pre-packaged alcohol friendly eCig. See more at: http://www.mCig.org/, www.Vapolution.com, www.VitaCig.org
The Company believes that a well regulated marijuana industry is emerging as more states follow the lead of Washington and Colorado in legalizing marijuana. A similar trend is developing within the eCig industry following the first acquisition of an electronic cigarette brand (Blucigs) by a traditional tobacco company Lorillard Inc. for $135 million followed by another acquisition in February 2014 by Altria Group Inc. of Green Smoke for $150 million. Wells Fargo analyst Bonnie Herzog estimates that eCig sales may rise from $1 Billion in 2013 to $10 billion over the next three years.
mCig, Inc. (OTCQB:MCIG) has positioned itself as a first mover at the intersection of these two trends and hopes to create shareholder value by making the mCig one of the leading choices for electronic consumption of plant material. - See more at: http://www.mcig.org/investors/investor-opportunity-subpage/
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, and future product commercialization; and the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies.
CONTACT: Paul Rosenberg
CEO
(425)462-4219
